ALK and non-small cell lung carcinoma: ALK-positive NSCLC patients have a high rate of response to these inhibitors, and these inhibitors can achieve a better clinical outcome and longer progression-free survival than other therapies; however, similar to other TKIs, most patients also develop drug resistance to ALK inhibitors [7].